EUVIMEDEUVIMED entdecken
Crossref

Clinically Relevant Mutational Signatures and Prognostic Biomarkers in Taiwanese Oral Squamous Cell Carcinoma

Chan-Chi Chang iD, Fang-Yu Tsai iD, Shang-Yin Wu iD, Yang-Kao Wang iD, Yu-Chu Su iD, Jenn-Ren Hsiao iD, Shih Sheng Jiang iD

Head & Neck · 07.07.2026

DOI: 10.1002/hed.70383 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Head & Neck, online erschienen am 07.07.2026. Verfasst von Chan-Chi Chang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Next-generation Pathway of Taiwan Cancer Precision Medicine Program (TCPMP), Bioinformatics Core Facility for Biotechnology and Pharmaceuticals under National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Oral squamous cell carcinoma (OSCC), primarily caused by high exposure to betel quid, tobacco, and alcohol, remains a major public health burden in Taiwan. Although key mutations have been identified in OSCC, the population‐specific mutational landscape and its clinical relevance remain underexplored.

Methods

A total of 106 OSCC tumors from Taiwanese patients were subjected to targeted gene sequencing with the Oncomine Comprehensive Assay v3 platform. High‐confidence exonic, nonsynonymous variants were identified from 161 cancer‐related genes. The resulting mutational landscape was compared with publicly available data from The Cancer Genome Atlas. Gene‐ and pathway‐level alterations were further correlated with clinicopathological parameters.

Results

A total of 317 exonic, nonsynonymous variants were identified in 73 OSCC‐related genes, of which 52 were classified as driver genes. In addition to commonly mutated genes (e.g., TP53 , CDKN2A , NOTCH1 , HRAS , and PIK3CA ), PIK3R1 and MSH6 exhibited high mutation frequencies. A higher number of mutated genes per tumor was significantly correlated with poorer local‐relapse‐free survival (hazard ratio: 1.17, 95% CI: 1.04–1.31, p = 0.010). In the 83 advanced‐stage OSCC tumors, TP53 mutation was strongly associated with positive cervical lymph nodal metastasis ( p < 0.001). An inverse relationship was noted between nodal metastasis and NOTCH1 , HRAS , and PIK3CA mutations, possibly due to the mutually exclusive pattern observed between TP53 and NOTCH1 / HRAS mutations. Alteration of the cell cycle oncogene pathway was significantly associated with poor survival in advanced‐stage OSCC patients, which was subsequently confirmed as an independent prognostic factor for disease‐specific survival (hazard ratio: 3.2, 95% CI: 1.05–9.75, p = 0.040) in 89 patients with advanced‐stage OSCC from The Cancer Genome Atlas.

Conclusions

This study uniquely illustrates the mutational landscape of OSCC in Taiwanese patients, highlighting clinically relevant genomic alterations that hold promise as prognostic biomarkers and candidates for targeted intervention.

Schlagwörter

Stichwörter der Autor:innen

mutation profilingoral squamous cell carcinomaprognostic biomarkerssurvival analysis

Autor:innen und Institutionen

  • Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Department of Otolaryngology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • National Institute of Cancer Research, National Health Research Institutes, Miaoli, Taiwan.
  • Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Department of Cell Biology and Anatomy, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

ORCID-Profile: Chan-Chi Chang, Fang-Yu Tsai, Shang-Yin Wu, Yang-Kao Wang, Yu-Chu Su, Jenn-Ren Hsiao, Shih Sheng Jiang

Förderung

  • Next-generation Pathway of Taiwan Cancer Precision Medicine Program (TCPMP)
  • Bioinformatics Core Facility for Biotechnology and Pharmaceuticals under National Science and Technology Council

Zitieren

APA

Chang, C. C., Tsai, F. Y., Wu, S. Y., Wang, Y. K., Su, Y. C., Hsiao, J. R., & Jiang, S. S. (2026). Clinically Relevant Mutational Signatures and Prognostic Biomarkers in Taiwanese Oral Squamous Cell Carcinoma. Head & Neck. https://doi.org/10.1002/hed.70383

Vancouver

Chang CC, Tsai FY, Wu SY, Wang YK, Su YC, Hsiao JR, et al. Clinically Relevant Mutational Signatures and Prognostic Biomarkers in Taiwanese Oral Squamous Cell Carcinoma. Head & Neck. 2026. doi:10.1002/hed.70383

BibTeX
@article{Chang2026,
  author = {Chang, Chan-Chi and Tsai, Fang-Yu and Wu, Shang-Yin and Wang, Yang-Kao and Su, Yu-Chu and Hsiao, Jenn-Ren and Jiang, Shih Sheng},
  title = {Clinically Relevant Mutational Signatures and Prognostic Biomarkers in Taiwanese Oral Squamous Cell Carcinoma},
  journal = {Head & Neck},
  year = {2026},
  doi = {10.1002/hed.70383}
}
Kostenlos starten →